References
Zachariah PK, Sheps SG, Schriger A. Efficacy of sustained-release verapamil: Automatic ambulatory blood pressure monitoring.J Clin Hypertens 1986;3:133S-142S.
Hla KK, Henry JA, Latham AN. Pharmacokinetics and pharmacodynamics of two formulations of verapamil.Br J Clin Pharmac 1987;24:661–664.
McMahon FG, Reder RF. The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension.J Clin Pharmacol 1989;29:1003–1007.
MacGregor GA. A randomised dose study of verapamil in patients with essential hypertension. In: Althaus U, Burckhardt D, Vogt E, eds.Calcium Antagonismus Internat.Symposium on Calcium-Antagonism. Frankfurt/Main: Verlag GmbH, 1984:125–126.
Antonicelli R, Tomassini PF, Galletti P, et al. Age-related antihypertensive and haemodynamic effects of verapamil SR: Clinical results and effects on atrial natriuretic peptide.Eur J Clin Pharmacol 1990;39(Suppl 1):S29-S33.
Pozenel H. The antihypertensive effect of slow release verapamil in relation to plasma concentrations. In: Fleckenstein A, Laragh JH, eds.Hypertension—The Next Decade: Verapamil in Focus, 1st ed. Edinburgh: Churchill Livingstone, 1987:298–301.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vulpis, V., Seccia, T.M., Ricci, S. et al. Study on antihypertensive efficacy of slow-release verapamil: Pharmacokinetic and noninvasive hemodynamic profile. Cardiovasc Drug Ther 7, 899–900 (1993). https://doi.org/10.1007/BF00877724
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00877724